- Home
- RPRX vs ALLE Comparison
RPRX vs ALLE Comparison
Compare RPRX & ALLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- ALLE
- Stock Information
- Founded
- RPRX 1996
- ALLE 2013
- Country
- RPRX United States
- ALLE Ireland
- Employees
- RPRX N/A
- ALLE N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- ALLE Diversified Commercial Services
- Sector
- RPRX Health Care
- ALLE Consumer Discretionary
- Exchange
- RPRX Nasdaq
- ALLE Nasdaq
- Market Cap
- RPRX 15.6B
- ALLE 12.7B
- IPO Year
- RPRX 2020
- ALLE N/A
- Fundamental
- Price
- RPRX $35.87
- ALLE $169.83
- Analyst Decision
- RPRX Strong Buy
- ALLE Hold
- Analyst Count
- RPRX 3
- ALLE 9
- Target Price
- RPRX $45.33
- ALLE $163.67
- AVG Volume (30 Days)
- RPRX 3.1M
- ALLE 771.5K
- Earning Date
- RPRX 08-06-2025
- ALLE 10-23-2025
- Dividend Yield
- RPRX 2.45%
- ALLE 1.20%
- EPS Growth
- RPRX 54.86
- ALLE 14.50
- EPS
- RPRX 2.32
- ALLE 7.20
- Revenue
- RPRX $2,305,243,000.00
- ALLE $3,876,600,000.00
- Revenue This Year
- RPRX $33.77
- ALLE $9.25
- Revenue Next Year
- RPRX $4.62
- ALLE $5.24
- P/E Ratio
- RPRX $15.45
- ALLE $23.57
- Revenue Growth
- RPRX 3.02
- ALLE 5.49
- 52 Week Low
- RPRX $24.05
- ALLE $116.57
- 52 Week High
- RPRX $38.00
- ALLE $172.95
- Technical
- Relative Strength Index (RSI)
- RPRX 42.45
- ALLE 60.04
- Support Level
- RPRX $35.48
- ALLE $169.35
- Resistance Level
- RPRX $36.99
- ALLE $172.95
- Average True Range (ATR)
- RPRX 0.68
- ALLE 2.65
- MACD
- RPRX -0.14
- ALLE -0.42
- Stochastic Oscillator
- RPRX 7.28
- ALLE 67.15
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.